Table 3 Impact of baseline patient characteristics on potency rates two years post-SBRT
From: Potency preservation following stereotactic body radiation therapy for prostate cancer
Characteristics | % Potent 2Â years after SBRT | p value | |
|---|---|---|---|
Age | Â | Â | Â |
|  | ≤ 65 y/o pre-RT | 66.7% | 0.580 |
| Â | >65 y/o pre-RT | 47.4% | Â |
Race | Â | Â | Â |
| Â | White | 51.2% | 0.574 |
| Â | Non-white | 57.4% | Â |
Partner status | Â | Â | Â |
| Â | Partnered | 54.3% | 0.297 |
| Â | Non-partnered | 55.0% | Â |
Charlson comorbidity index (CCI) | Â | Â | |
| Â | 0 | 58.9% | 0.007* |
|  | ≥1 | 35.3% |  |
Body mass index (BMI) | Â | Â | |
| Â | < 30 | 60.9% | 0.943 |
|  | ≥ 30 | 38.5% |  |
Risk group (D’ Amico’ s) |  |  | |
| Â | Low risk | 54.8% | 0.420 |
| Â | Intermediate-High Risk | 54.2% | Â |
Work status | Â | Â | |
| Â | Working | 54.7% | 0.173 |
| Â | Non-working | 54.1% | Â |
Pre- treatment SHIM | Â | Â | |
|  | ≥ 22 | 40.91% | 0.127 |
| Â | < 22 | 67.39% | Â |
Sexual aid | Â | Â | Â |
| Â | None | 43.8% | 0.010*# |
| Â | Yes | 60.3% | Â |
SBRT Dose | Â | Â | Â |
| Â | 36.25 Gy | 50.0% | 0.933 |
| Â | < 36.25 Gy | 55.0% | Â |